Hemophilia B - Pipeline Review, H2 2016

Date: September 30, 2016
Pages: 112
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H53B1CA925BEN
Leaflet:

Download PDF Leaflet

Hemophilia B - Pipeline Review, H2 2016
Hemophilia B - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2016, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 6, 6, 1, 6 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Hemophilia B.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hemophilia B Overview
Therapeutics Development
Pipeline Products for Hemophilia B - Overview
Pipeline Products for Hemophilia B - Comparative Analysis
Hemophilia B - Therapeutics under Development by Companies
Hemophilia B - Therapeutics under Investigation by Universities/Institutes
Hemophilia B - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hemophilia B - Products under Development by Companies
Hemophilia B - Products under Investigation by Universities/Institutes
Hemophilia B - Companies Involved in Therapeutics Development
Alnylam Pharmaceuticals, Inc.
Amarna Therapeutics B.V.
Bayer AG
Biogen Inc
Catalyst Biosciences, Inc.
China Biologic Products, Inc.
CSL Limited
Dimension Therapeutics, Inc.
Green Cross Corporation
MolMed S.p.A.
Novo Nordisk A/S
OPKO Biologics Ltd
Pfizer Inc.
Pharming Group N.V.
RegenxBio Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Shire Plc
Spark Therapeutics, Inc.
UniQure N.V.
Hemophilia B - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMT-060 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAX-335 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1093884 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-2679d - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Hemophilia B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor IX (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor IX (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor IX (recombinant), albumin fusion protein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor IX (recombinant), pegylated - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor VIIa (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
concizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-689 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DTX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fitusiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Hemophilia B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Hemophilia B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LR-769 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
marzeptacog alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-1113A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-5014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06741086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Factor IX Replacement for Hemophilia B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-FIX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPK-9001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SVF-VIIa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hemophilia B - Dormant Projects
Hemophilia B - Discontinued Products
Hemophilia B - Product Development Milestones
Featured News & Press Releases
Sep 26, 2016: Alprolix obtains reimbursement across the United Kingdom
Sep 07, 2016: Catalyst Biosciences to Focus on Improved Factor IX Clinical Hemostasis Program
Sep 06, 2016: Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing
Jul 26, 2016: CSL Behring Presents Phase III Data for IDELVION for Hemophilia B at the World Federation of Hemophilia 2016 World Congress
Jul 25, 2016: Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders
Jul 25, 2016: Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia 2016 World Congress
Jul 19, 2016: CSL Behring to Present New Data for IDELVION at the World Federation of Hemophilia 2016 World Congress
Jul 18, 2016: Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data on ALPROLIX at World Federation of Hemophilia 2016 World Congress
Jun 06, 2016: Sobi: First Alprolix sales in the EU
May 24, 2016: Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst Next-Generation Factor VIIa Product CB 813d
May 16, 2016: Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of hemophilia B
May 13, 2016: Alprolix (rFIXFc) approved in the EU for the treatment of hemophilia B
May 12, 2016: IDELVION (rFIX-FP) - European Commission Approval
May 11, 2016: CSL Behring's Innovative Therapy for Hemophilia B Patients, IDELVION, Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug Administration
May 11, 2016: European Commission Approves IDELVION --CSL Behring Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 112

LIST OF TABLES

Number of Products under Development for Hemophilia B, H2 2016
Number of Products under Development for Hemophilia B - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Hemophilia B - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
Hemophilia B - Pipeline by Amarna Therapeutics B.V., H2 2016
Hemophilia B - Pipeline by Bayer AG, H2 2016
Hemophilia B - Pipeline by Biogen Inc, H2 2016
Hemophilia B - Pipeline by Catalyst Biosciences, Inc., H2 2016
Hemophilia B - Pipeline by China Biologic Products, Inc., H2 2016
Hemophilia B - Pipeline by CSL Limited, H2 2016
Hemophilia B - Pipeline by Dimension Therapeutics, Inc., H2 2016
Hemophilia B - Pipeline by Green Cross Corporation, H2 2016
Hemophilia B - Pipeline by MolMed S.p.A., H2 2016
Hemophilia B - Pipeline by Novo Nordisk A/S, H2 2016
Hemophilia B - Pipeline by OPKO Biologics Ltd, H2 2016
Hemophilia B - Pipeline by Pfizer Inc., H2 2016
Hemophilia B - Pipeline by Pharming Group N.V., H2 2016
Hemophilia B - Pipeline by RegenxBio Inc., H2 2016
Hemophilia B - Pipeline by rEVO Biologics, Inc., H2 2016
Hemophilia B - Pipeline by Sangamo BioSciences, Inc., H2 2016
Hemophilia B - Pipeline by Shire Plc, H2 2016
Hemophilia B - Pipeline by Spark Therapeutics, Inc., H2 2016
Hemophilia B - Pipeline by UniQure N.V., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hemophilia B - Dormant Projects, H2 2016
Hemophilia B - Discontinued Products, H2 2016 98

LIST OF FIGURES

Number of Products under Development for Hemophilia B, H2 2016
Number of Products under Development for Hemophilia B - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Hemophilia A - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 159 pages

Ask Your Question

Hemophilia B - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: